Menu
Menu
Menu
Our novel proprietary multi-cancer screening
platform will make cancer screening
ACCURATE
ACCESSIBLE
AFFORDABLE
ACCEPTABLE
and create value for all stakeholders,
across the screening and treatment pipeline:
Our novel proprietary multi-cancer screening platform will make cancer screening:
ACCURATE
ACCESSIBLE
AFFORDABLE
ACCEPTABLE
and create value for all stakeholders,
across the screening and treatment pipeline:
Safe & convenient way to take control over their health
Increase chances of survival
Remove barriers for screening
Reduce geographical and economic disparities
Remove system barriers
Safe & convenient way to take control over their health
Increase chances of survival
Remove barriers for screening
Reduce geographical and economic disparities
Remove system barriers
Remove system barriers
Promote Innovation
SAFE
ACCURATE
SIMPLE
MULTI-CANCER
AFFORDABLE
It has been well known to science for many years that tumors secrete materials (Volatile Organic Compounds – VOCs) into a person’s bloodstream, urine, and other body secretion. This generally happens from the earliest days of the tumor’s formation.
These materials have distinct odors which are available for diagnostic testing. Many techniques to detect these molecular markers of cancer are being explored, but none have matured into a working, scalable, screening test.
At EARLY, we created a novel multi-cancer screening platform, the Biosensor Platform (BSP) Urine Test, to make cancer screening accurate, safe, non-invasive, simple, cost effective and accessible to people around the world, starting with lung cancer.
It has been well known to science for many years that tumors secrete materials (Volatile Organic Compounds – VOCs) into a person’s bloodstream, urine, and other body secretion. This generally happens from the earliest days of the tumor’s formation.
These materials have distinct odors which are available for diagnostic testing. Many techniques to detect these molecular markers of cancer are being explored, but none have matured into a working, scalable, screening test.
At EARLY, we created a novel multi-cancer screening platform, the Biosensor Platform (BSP) Urine Test, to make cancer screening accurate, safe, non-invasive, simple, cost effective and accessible to people around the world, starting with lung cancer.
It is a well establish scientific fact that tumors secrete Volatile Organic Compounds into bodily fluids such as blood, saliva and urine, and that this occurs from the earliest stages of the tumor’s formation.
In recent years several technologies have been explored to develop electronic noses and gas-analyzers that will detect the VOCS molecular markers of cancer, and identify the cancer odor signature, but none have matured into a working, scalable, diagnostic test.
Here at EARLY we have developed the BSP – a multi-cancer bio-sensor test platform – currently focusing on lung cancer – to detect cancer VOC signatures in urine samples from its earliest stages using a patented technology combining Machine Learning, AI and unique biosensors – with 92% stage I sensitivity and 88% specificity clinical trials results.
EARLY is the world’s pioneer provider of VM (Volatile Markers) test for early detection of cancer.
The key to fighting cancer is early detection, meaning finding the disease when it is still curable. Our test is specially designed to meet the needs and demands of large-scale population/targeted screening programs, by being acceptable, affordable and accessible.
With a simple, safe, highly sensitive, inexpensive urine test, EARLY’s proprietary evidence-based novel platform will enable diagnostic level testing on a population screening scale.
The company’s test will revolutionize the way cancer is detected, starting with lung cancer, and dramatically reduce the disease’s global human and financial burden.
In the future, the same technology will be modified to allow detection of other cancer types, creating a unique multi-cancer screening platform.
Lung cancer remains the leading cause of cancer-related deaths. While recent therapies offer hope, early detection is crucial for effective treatment and improved outcomes. Current screening methods like low-dose CT scans have limitations, including high false-positive rates and limited accessibility, resulting in low adoption rates and late-stage diagnoses.
EARLY Labs is an innovative Biotech startup that has developed a novel approach to cancer detection using Volatile Organic Compounds (VOCs) present in urine as a biomarker. Our revolutionary test platform provides early-stage detection through a non-invasive, easy to self-administer, urine test, and validated results of 92% sensitivity and 88% specificity in detecting lung cancer, even in its early stages. Our pipeline includes utilizing the platform for the development of tests for other types of cancer as well.
The EARLY Labs team is led by Dr. Michal Mark Danieli, PhD, a distinguished expert in cell biology and immunology. As the Founder and CEO, Dr. Danieli brings a wealth of experience from her tenure as a senior researcher at Sheba Medical Center and her role in founding multiple health and cancer research startups. Her leadership exemplifies the strength and innovation of women entrepreneurs in the biotech industry.
EARLY is the world’s pioneer provider of VM (Volatile Markers) test for early detection of cancer.
The key to fighting cancer is early detection, meaning finding the disease when it is still curable. Our test is specially designed to meet the needs and demands of large-scale population/targeted screening programs, by being acceptable, affordable and accessible.
With a simple, safe, highly sensitive, inexpensive urine test, EARLY’s proprietary evidence-based novel platform will enable diagnostic level testing on a population screening scale.
Our team comprise of highly experienced multidisciplinary experts in the fields of Biology, Zoology, Engineering, Bioinformatics and Marketing.
PhD in Cell Biology & Immunology.
Ex-senior researcher at Sheba.
Founded several startups in the health-cancer space.
PhD in Cell & Molecular Biology with expertise in cancer and neurodegenerative diseases.
Experienced lab manager and team leader.
Animal behavior expert. Over 25 years of experience in training animals for operational tasks. Served over 20 years in Israeli Navy Seals in a special R&D unit. B.Sc. in Behavioral Science from Ben Gurion University
PhD in Electrical and Electronics engineering, over a decade of hands-on and leadership experience in data science and machine learning, building systems from POC to production.
an international MedTech R&D leader. In his 20 years at Boston Scientific, as VP R&D led PI and Vascular R&D portfolio driving all aspects of development end-to-end. board member of several research
institutes and life science companies, and a regular speaker in
world leading MedTech Conferences and conventions.
Over 20 years of international experience in senior leadership roles in business development, strategy and general management within the healthcare industry
Professor Navani is a lead clinician for the lung cancer services at UCLH, senior clinical lead of the UK National Lung Cancer Audit , Respiratory representative on the NICE lung cancer guideline. Chairs the lung cancer board for the North Central and East London Cancer Alliance.
With over a 25 years of experience Dr. Jefferey Scott is a leader in the field Medical Oncology in the US, building market leading initiatives and bringing to the marketplace numerous innovative products and programs.
Co-founder and former President of the International Oncology Network (ION)
Thoracic surgical oncology expert, with over 20 years of experience leading pulmonary research in several medical centers.
Professor Wiesel is a Thoracic and Esophageal Surgery expert.
Innovation leader in diagnosis and treatment of lung cancer.
24.12.2025
Aligned with Assuta’s commitment to advancing healthcare outcomes, streamlining diagnostic workflows, fostering innovation, and reducing the time and cost of diagnoses, this collaboration focuses on evaluating and planning use cases for EARLY Labs’ AI-driven urine-based test, which analyzes Volatile Organic Compound biomarkers.
24.12.2025
We’re delighted to share that Check4Cancer has partnered with EARLY Labs to develop a non-invasive, urine-based early cancer detection test powered by AI and machine learning.
By analysing cancer-associated volatile organic compounds (VOCs) in urine, this innovative technology has already shown high sensitivity for lung cancer detection. Together, we’ll focus on evidence-based validation and commercialisation to make early detection simpler, more accessible, and more accurate — for self-pay, insured and corporate markets in the UK and beyond.
19.11.2025
From building a globally used PREDICT breast cancer model to using facial scans and machine learning to identify early warning signs, Professor Gordon Wishart, a cancer surgeon, researcher, and founder of Check4Cancer, breaks down what’s holding back the shift to proactive care and what needs to change.
19.08.2025
Early detection and diagnosis is key in reduction of lung cancer incidence worldwide.
01.06.2025
09.02.2025
Excited and proud to share our publication in a special edition of the Journal of Clinical Medicine on the topic of Clinical Research Advances in Thoracic Surgery.
The paper details a joint study led by Professor Ory Wiesel, MD from the Tzafon Medical Center outlining 5 real world patient cases demonstrating clear benefits of using EARLY’s lung cancer early detection urine test as a decision support tool to the existing lung cancer diagnostic and treatment pathways. This is our 2nd published paper in a scientific peer reviewed journal.
23.10.2024
01.08.2024
One key takeaway – developing an effective, non-invasive, early detection cancer screening test remains a major unmet challenge (but hopefully not for long…..).
28.05.2024
18.04.2024
19.12.2023
Funded by HHS, and Operated by the Israeli American Chamber of Commerce, Mass General Hospital, and ARMI, 6 selected Israeli startup participated in an amazing 3 week program, meeting with clinical leaders and business field experts all in the purpose accelerating new and promising Israeli technologies into the US market.
10.08.2023
11.07.2023
MDPI
08.06.2023
Daily Mail
08.05.2023
